Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven ...

Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion ...

The cancer antigen therapy mRNA-4359 yielded a high rate of antitumor responses in combination with pembrolizumab (Keytruda) ...

New research suggests hair loss may hinge on a fragile cellular balance during regeneration, where stem cells must survive a ...

Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the ...

Systemic inflammation research occupies a pivotal position at the intersection of immunology, metabolism, and disease pathogenesis. Recent advances have ...

Most e-bike batteries on the market today use conventional lithium-ion cells that deliver somewhere between 40 and 80 miles ...

Manufacturers invest heavily in advanced cutting tools, high-performance CNC machines, and optimized cutting strategies, and ...

Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

HIV-1 envelope glycoprotein (Env), a gp120–gp41 trimer, undergoes coordinated conformational changes that drive membrane fusion and allow immune evasion by transiently concealing ...

PureTech Health plc ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced positive topline ...